Omeprazole
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1989
- First approval year
- 1989
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Omeprazole
- Molecular weight
- 345.42
- Structure (SMILES)
- COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1
- antra
- Antra
- losec
- Losec
- losec mups
- Losec mups
- mezzopram
- Mezzopram
- mopral
- Mopral
- omeprazole
- Omeprazole
- omeprazole component of konvomep
- Omeprazole component of konvomep
- omeprazole component of pa 32540
- Omeprazole component of pa-32540
- omeprazole component of yosprala
- Omeprazole component of yosprala
- omeprazole component of zegerid
- Omeprazole component of zegerid
- omeran
- Omeran
- prilosec
- Prilosec
- zanprol
And 1 more, listed on the interactive page.
- h 168 68
- H 168/68
- H-168/68
- h168 68
- H168/68
- losec mups 20 mg
- nsc 751450
- nsc 759192
- NSC-751450
- NSC-759192
- omeprazol
- Omeprazol
- omeprazole
- Omeprazole
- Omeprazole [EP MONOGRAPH]
- Omeprazole [GREEN BOOK]
- Omeprazole [HSDB]
- Omeprazole [INN]
- Omeprazole [JAN]
- Omeprazole [MART.]
- Omeprazole [MI]
- Omeprazole [ORANGE BOOK]
- Omeprazole [USAN]
- Omeprazole [USP IMPURITY]
- Omeprazole [USP MONOGRAPH]
And 23 more, listed on the interactive page.
- ATC classification codes
- A02BC01
Sources for recorded values
- CAS registry numbers
- 73590-58-6
- ChEMBL ID
- CHEMBL1503
- InChIKey
- SUBDBMMJDZJVOS-UHFFFAOYSA-N
- PubChem compound IDs
- 4594
- FDA ingredient codes (UNII)
- KG60484QX9
- 7646
- 283742
- Applicant
- DEXCEL PHARMA
- Approval date
- 4 Dec 2007
- Application number
- NDA022032
- Patents
- 2
- Designations
- 2
- Earliest recorded loss of exclusivity
- 8 Dec 2036
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- United States (FDA)
- Approved
- Pharmacology name
- omeprazole
- Type
- Synthetic organic
- Drug name stem
- -prazole
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Activator
- Action type
- ACTIVATOR
- Target
- ClC-2
- Gene symbol
- CLCN2
- Protein identifier
- P51788
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- ATP4A
- Gene symbol
- ATP4A
- Protein identifier
- P20648
- Primary target
- Yes
- Mechanism
- Potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Potassium-transporting ATPase
- Protein identifier
- P20648
- Mechanism
- Potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Potassium-transporting ATPase
- Protein identifier
- P51164
Open Targets mechanisms
- Mechanism
- Potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Potassium-transporting ATPase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- ATP4A|ATP4B
- Protein identifier
- P20648|P51164
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Lymphoma, B-Cell, Marginal Zone
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000191
- Subject identifier
- D018442
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Gastritis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000217
- Subject identifier
- D005756
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Barrett Esophagus
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000280
- Subject identifier
- D001471
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Crohn Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Wounds and Injuries
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Psoriasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
And 49 more, listed on the interactive page.
- Condition identifier
- EFO_0000217
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000546
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000685
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001645
- Condition identifier
- EFO_0002618
- Condition identifier
- EFO_0003047
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003095
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003100
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003756
- Condition identifier
- EFO_0003898
- Condition identifier
- EFO_0003929
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003948
- Condition identifier
- EFO_0004149
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004232
- Condition identifier
- EFO_0004234
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 1
And 90 more, listed on the interactive page.
- Event
- acute kidney injury
- Reports
- 2,774
- Reporting signal score
- 2,878.03
- Event
- blood calcium decreased
- Reports
- 241
- Reporting signal score
- 373.137
- Event
- chronic kidney disease
- Reports
- 2,973
- Reporting signal score
- 8,596.4
- Event
- creatinine renal clearance decreased
- Reports
- 182
- Reporting signal score
- 358.219
- Event
- drug interaction
- Reports
- 1,620
- Reporting signal score
- 658.177
- Event
- end stage renal disease
- Reports
- 642
- Reporting signal score
- 1,717.96
- Event
- gastrooesophageal reflux disease
- Reports
- 769
- Reporting signal score
- 638.972
- Event
- hypocalcaemia
- Reports
- 1,124
- Reporting signal score
- 2,036.96
- Event
- hypokalaemia
- Reports
- 919
- Reporting signal score
- 862.225
- Event
- hypomagnesaemia
- Reports
- 1,868
- Reporting signal score
- 4,948.73
- Event
- hyponatraemia
- Reports
- 1,945
- Reporting signal score
- 2,526.12
- Event
- rebound acid hypersecretion
- Reports
- 101
- Reporting signal score
- 413.951
- Event
- renal failure
- Reports
- 1,041
- Reporting signal score
- 641.183
- Event
- renal injury
- Reports
- 660
- Reporting signal score
- 1,606.76
- Event
- sedation complication
- Reports
- 179
- Reporting signal score
- 507.811
- Event
- subacute cutaneous lupus erythematosus
- Reports
- 313
- Reporting signal score
- 832.81
- Event
- tetany
- Reports
- 147
- Reporting signal score
- 387.842
- Event
- tubulointerstitial nephritis
- Reports
- 1,124
- Reporting signal score
- 2,304.38
- NCT00001191
- NCT00002682
- NCT00003151
- NCT00298779
- NCT00003617
- NCT00164866
- NCT00247130
- NCT00374101
- NCT00164931
- NCT03362268
- NCT03362281
- NCT04170270
- NCT00201422
- NCT00210470
- NCT00256737
- NCT00259051
- NCT00259077
- NCT00426595
- NCT00537732
- NCT00564590
- NCT00693225
- NCT00818870
- NCT00857597
- NCT01136317
- NCT01269788
And 115 more, listed on the interactive page.
- Dose
- 20 mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Take before meals
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 83.09
- Calculated partition coefficient (ALogP)
- 2.9
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- Yes
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 24
- Molecular formula
- C17H19N3O3S
- Monoisotopic mass
- 345.11471265
- Natural product
- Yes
- 0615-8079
- 0615-8406
- 0781-2234
- 0781-2785
- 0781-2790
- 0781-2859
- 0781-2868
- 0904-6917
- 16714-123
- 16714-630
- 16714-634
- 16714-714
- 27241-029
- 27241-030
- 27241-031
- 27241-032
- 31722-527
- 31722-528
- 42708-158
- 42708-159
- 42708-170
- 42708-199
- 43063-743
- 43353-829
- 49999-265
And 172 more, listed on the interactive page.
- Recorded assays
- 6,271
- Active assays
- 319
- Confirmatory
- Other
- Screening
- Summary
- Anti-Ulcer Agents
- Proton Pump Inhibitors
These details could not be displayed.
Related records
Trials (375)
- "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
- A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole
- A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects
- A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
- A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations
- A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
- A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin
- A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)
- A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
- A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
- A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
- A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
- A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
- A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults
Approved for (8)
- Arthritic joint disease
- Duodenal ulcer
- Dyspepsia
- Esophagitis
- Gastric ulcer
- Gastroesophageal reflux disease
- Peptic ulcer disease
- Spondylitis
In development for (73)
- Acute kidney injury Phase 2
- Acute myeloid leukemia Phase 1
- Alzheimer disease Phase 1
- Anemia Phase 1
- Ankylosing spondylitis Phase 3
- Atopic eczema Phase 1
- Autism spectrum disorder Phase 1
- Barrett esophagus Phase 3
- Breast cancer Phase 2
- Breast carcinoma Phase 2
- Cancer Phase 1
- Cardiovascular disorder Phase 1
- Central serous chorioretinopathy Phase 1
- Chronic gastritis Phase 2
- Chronic hepatitis B virus infection Phase 1
- Chronic hepatitis C virus infection Phase 1
- Chronic obstructive pulmonary disease Phase 1
- Clostridium infectious disease Phase 1
- Colorectal cancer Phase 2
- Congenital laryngomalacia Phase 1
Other linked conditions (5)
- Bacterial infectious disease
- Coronary artery disorder
- Depressive disorder
- Eosinophilic esophagitis
- Gastric mucosa-associated lymphoid tissue lymphoma